Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abratt, R. P.
Right arrow Articles by Hacking, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abratt, R. P.
Right arrow Articles by Hacking, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 15, 744-749, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

RP Abratt, WR Bezwoda, L Goedhals and DJ Hacking
University of Cape Town, South Africa. RPAORAY@UCT.AC.ZA

PURPOSE: The aim of this study was to examine the efficacy of a regimen of initial gemcitabine followed by cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Fifty-three patients (36 men and 17 women; age range, 35 to 74 years) were enrolled. Patients had bidimensionally measurable disease. Gemcitabine (phase-specific agent) was administered on days 1, 8, and 15 at a dose of 1,000 mg/m2. Cisplatin (cycle-specific agent) was administered on day 15 (100 mg/m2). Chemotherapy was administered in 28-day cycles. RESULTS: Of 53 patients enrolled, 50 were assessable for response. The overall response rate was 52%. There were two complete responses (4%) and 24 partial responses (48%). The median survival duration was 13 months and the 1-year survival rate was 61%. The regimen was generally well tolerated. World Health Organization (WHO) grade 3 and 4 neutropenia occurred in 38.8% and 19.2% of patients, respectively. Grade 3 and 4 thrombocytopenia occurred in 13.3% and 7.7% of patients, respectively. Most patients experienced mild nausea and vomiting. Few patients had hair loss and oral toxicity was mild. Relatively few patients required dose modifications for any of the three weekly doses of chemotherapy. For the first two cycles of chemotherapy, the dose- intensity per infusion was 947 mg/m2 for gemcitabine and 85 mg/m2 for cisplatin. CONCLUSION: This regimen of gemcitabine and cisplatin was effective, with high response and survival rates and few dosage modifications during its administration. Prospective randomized studies with other cisplatin-based combination chemotherapy regimens are indicated.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al.
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
Ann. Onc., March 1, 2010; 21(3): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Belani, S Dakhil, D. Waterhouse, C. Desch, D. Rooney, R. Clark, M. Monberg, Z Ye, and C. Obasaju
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer
Ann. Onc., January 1, 2007; 18(1): 110 - 115.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Compr Canc NetwHome page
D. M. Dunning and T. A. Paivanas
Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology
J Natl Compr Canc Netw, January 1, 2006; 4(1): 3 - 15.
[Abstract] [PDF]

Home page
 Ann OncolHome page
S. Faivre, T. Le Chevalier, C. Monnerat, F. Lokiec, S. Novello, J. Taieb, P. Pautier, C. Lhomme, P. Ruffie, L. Kayitalire, et al.
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
Ann. Onc., September 1, 2002; 13(9): 1479 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, J. Boukovinas, G. Fountzilas, D. Skarlos, T. Economopoulos, D. Tsavdaridis, et al.
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial
J. Clin. Oncol., September 1, 2002; 20(17): 3578 - 3585.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. C.M. Pitz, K. W. Maas, H. A. V. Swieten, A. Brutel de la Riviere, P. Hofman, and F. M.N.H. Schramel
Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer
Ann. Thorac. Surg., July 1, 2002; 74(1): 164 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Soto Parra, R. Cavina, F. Latteri, A. Sala, M. Dambrosio, G. Antonelli, E. Morenghi, M. Alloisio, G. Ravasi, and A. Santoro
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Ann. Onc., July 1, 2002; 13(7): 1080 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Kusaba, T. Tamura, T. Shimoyama, K. Hotta, A. Inoue, H. Nokihara, Y. Ueda, Y. Akiyama, N. Yamamoto, I. Sekine, et al.
Phase I/II Study of 3-Week Cycle Cisplatin-Gemcitabine in Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 43 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al.
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3942 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Patnaik, E. K. Rowinsky, B. K. Tammara, M. Hidalgo, R. L. Drengler, A. M. Garner, L. L. Siu, L. A. Hammond, S. A. Felton, S. Mallikaarjun, et al.
Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer
J. Clin. Oncol., December 1, 2000; 18(23): 3974 - 3985.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. C. H. Chen, M.-C. Lin, J. W. C. Chang, S.-W. Wang, C.-H. Lee, and T. C. Y. Tsao
Phase II Study of Regimen of Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 494 - 498.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Nishizaka, S. Gomi, K. Harada, K. Oizumi, K. Itoh, and S. Shichijo
A New Tumor-Rejection Antigen Recognized by Cytotoxic T Lymphocytes Infiltrating into a Lung Adenocarcinoma
Cancer Res., September 1, 2000; 60(17): 4830 - 4837.
[Abstract] [Full Text]

Home page
 JCOHome page
N. Van Zandwijk, E. F. Smit, G. W. P. Kramer, F. Schramel, S. Gans, J. Festen, A. Termeer, N. J. J. Schlosser, C. Debruyne, D. Curran, et al.
Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non-Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
J. Clin. Oncol., July 14, 2000; 18(14): 2658 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. P. Venook, M. J. Egorin, G. L. Rosner, D. Hollis, S. Mani, M. Hawkins, J. Byrd, R. Hohl, D. Budman, N. J. Meropol, et al.
Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565
J. Clin. Oncol., July 14, 2000; 18(14): 2780 - 2787.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Kelly
New Chemotherapy Agents for Small Cell Lung Cancer
Chest, April 1, 2000; 117 (2009): 156S - 162S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Nemunaitis, S. G. Swisher, T. Timmons, D. Connors, M. Mack, L. Doerksen, D. Weill, J. Wait, D. D. Lawrence, B. L. Kemp, et al.
Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2000; 18(3): 609 - 609.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Pectasides, A. Aspropotamitis, A. Halikia, A. Visvikis, F. Antoniou, A. Kalantaridou, N. Karvounis, S. Batzios, and A. Athanassiou
Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase II Study
J. Clin. Oncol., December 1, 1999; 17(12): 3816 - 3821.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Crino, G. V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, et al.
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
J. Clin. Oncol., November 1, 1999; 17(11): 3522 - 3530.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, et al.
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
J. Clin. Oncol., October 1, 1999; 17(10): 3188 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Frasci, N. Panza, G. Comella, and G. Pacilio
Is There Any Impact of New Drugs on the Outcome of Advanced NSCLC? An Overview of the Southern Italy Cooperative Oncology Group Trials
Oncologist, October 1, 1999; 4(5): 379 - 385.
[Abstract] [Full Text]

Home page
 JCOHome page
G. Frasci, N. Panza, P. Comella, G. P. Nicolella, M. Natale, L. Manzione, D. Bilancia, R. Cioffi, L. Maiorino, G. De Cataldis, et al.
Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study
J. Clin. Oncol., August 1, 1999; 17(8): 2316 - 2316.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Sandler and D. S. Ettinger
Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer
Oncologist, June 1, 1999; 4(3): 241 - 251.
[Abstract] [Full Text]

Home page
 JCOHome page
P. Comella, G. Frasci, N. Panza, L. Manzione, V. Lorusso, G. Di Rienzo, R. Cioffi, G. De Cataldis, L. Maiorino, D. Bilancia, et al.
Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group
J. Clin. Oncol., May 1, 1999; 17(5): 1526 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al.
Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial
J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al.
Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 1999; 17(3): 921 - 921.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cardenal, M. P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, A. Carrato, I. Barneto, M. Lomas, M. Garcia, P. Lianes, et al.
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
J. Clin. Oncol., January 1, 1999; 17(1): 12 - 12.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Byrne, J. A. Davidson, A. W. Musk, J. Dewar, G. van Hazel, M. Buck, N. H. de Klerk, and B. W.S. Robinson
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
J. Clin. Oncol., January 1, 1999; 17(1): 25 - 25.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo
Gemcitabine: Future Prospects of Single-Agent and Combination Studies
Oncologist, June 1, 1997; 2(3): 127 - 134.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online